CALVIN LEE: Open Payments
NPI 1003117136 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,631 in 50 payments from 11 companies in 2025. Trend: 2023 $609 · 2024 $819 · 2025 $1,631
Food & beverage: $1,631
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 15 | $676 |
| Gilead Sciences, Inc. | 9 | $334 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $243 |
| Ipsen Biopharmaceuticals, Inc | 5 | $163 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Intra-Sana Laboratories | 2 | $43 |
| Invivyd Inc | 1 | $33 |
| ABBVIE INC. | 1 | $32 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $22 |
| Mirum Pharmaceuticals, Inc. | 1 | $18 |
Products named: REZDIFFRA, XIFAXAN, IQIRVO, Livdelzi, TERLIVAZ, PEMGARDA, MAVYRET, JARDIANCE.
Industry payments across NY — which companies pay providers there.
